==== Front J Dent (Shiraz) J Dent (Shiraz) Journal of Dentistry 2345-6485 2345-6418 Shiraz University of Medical Sciences Iran JDS-21-4 10.30476/DENTJODS.2020.84667.1096 Original Article Serum Levels of IL-22 in Patients with Oral Lichen Planus and Cutaneous Lichen Planus Mardani Maryam DMD,MScD1 Torabi Ardakani Shiva DMD,MScD1 Dastgheib Ladan MD2 Hamidizadeh Nasrin PhD2 1 Oral and Dental Disease Research Center, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran 2 Molecular Dermatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran Corresponding author: Hamidizadeh N, Molecular Dermatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. P.O. Box: 71348-44119, Tel: +98-7132125592, Fax: +98-7132319049, Email: n.hamidizadeh.mdrc@gmail.com, nhamidizadeh@gmx.net 12 2020 21 4 330 334 7 8 2019 11 1 2020 1 6 2019 Copyright: © Journal of DentistryThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 Unported License, ( http://creativecommons.org/licenses/by/4.0/ ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Statement of the Problem: Lichen planus disease is a chronic inflammatory disorder of mucosal and cutaneous tissues with yet unclear etiology and pathogenesis. Cytokines play an important role in the initiation, maintenance of inflammatory and intercellular crosstalk. Purpose: We assessed serum levels of IL-22 in patients with oral and cutaneous lichen planus and made comparison with healthy individuals. Materials and Method: In this case-control study, peripheral blood samples of 40 patients with lichen planus disease, included two groups of oral lichen planus (n=20) and cutaneous lichen planus (n=20) were compared with 32 healthy individuals in this case-control study. Serum samples were prepared from patients with lichen planus and IL-22 concentration was measured in each serum sample by using a commercial ELISA Kit. The obtained data were then analyzed using the Kruskal-Wallis (one-way ANOVA) test. Results: The IL-22 serum levels were significantly higher in patients with oral lichen planus compared to the healthy control group (p< 0.001). No statistically significant differences were observed in serum levels of IL-22 in cutaneous lichen planus patients compared to the controls (p= 0.183). Conclusion: Increased IL-22 serum levels in patients with oral lichen planus may play an important role in the pathogenesis of oral lichen planus. The administration of the recombinant or antagonist of IL-22 could be a new therapeutic opportunity in the treatment of oral lichen planus. IL-22 Oral lichen planus Cutaneous lichen planus Serum ==== Body Introduction Lichen planus (LP) is a chronic and T cell-mediated inflammatory disorder of the skin and mucous membranes, which is classified based on the tissue involved, such as oral lichen planus (OLP), cutaneous lichen planus (CLP) and oral-cutaneous lichen planus [ 1 - 2 ]. LP affects about 0.5-2% of the general population, especially females, and most often occurs in middle age [ 3 ]. LP lesions can be symptomless, annular, linear, hypertrophic, atrophic, bullous, ulcerative, and pigmented [ 4 ]. Clinically, CLP is characterized by purple, polygonal, pruritic papules frequently covered by Wickham striae, located on the flexor surface, of the wrist, the shins, the trunk, and the medial thighs [ 5 ]. A basic clinical diagnosis of OLP can be made by Wickham striae [ 6 ]. It is reported that 0.4% to 5.3% of OLP lesions are transformed into carcinoma, making it a pre-malignant condition [ 7 ]. The etiology and pathogenesis of LP is unclear, but the combination of mast cell degranulation and matrix and matrix metalloproteinase activation in OLP lesions leads to T cell accumulation in the superficial lamina propria, basal membrane disruption, intraepithelial T cell migration, and keratinocyte apoptosis [ 8 ]. The majority of infiltering immune cells into epithelial layer and lamina propria are CD8+T and CD4+T cells, respectively [ 8 - 9 ]. Local and systemic inducers of cell-mediated hypersensitivity, autoimmune responses to epithelial antigens, viral infections, some systemic medications, dental material, stress, genetics, and tobacco chewing have been reported to be the triggering factors for OLP [ 10 - 11 ]. Cytokines play an important role in recruitment, differentiation, and activation of immune cells into inflammatory sites. Cytokines are soluble proteins with a low molecular weight that are produced by various cells, which play a complex role in the initiation, progression, and regression of autoimmune inflammation [ 12 ]. They regulate the immune responses by binding to cell surface receptors. IL-22 is a member of IL-10 superfamily that uses IL-22R1/IL-10R2 for cell signaling in target cells, produced by Th17, Th22, NK, innate lymphoid cells and various types of CD4+ and CD8+ T lymphocytes [ 13 ]. The IL-22 production is expressed in IL-23 in a dependent manner [ 14 - 16 ]. Several studies showed that IL-23, IL-18, and IL-6 increase the release of IL-22 [ 17 - 18 ]. IL-22 plays an important role in immune responses, par ticularly in inflammatory and autoimmune diseases in humans and animals [ 19 ]. IL-22 might have a protective, regenerative, or pathogenic role depending on the disease stage [ 20 - 22 ]. It is reported that IL-22 is involved in the development and pathogenesis of several autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, sjögren syndrome, and psoriasis [ 21 ]. IL-22 has a protective role in liver diseases and graft versus host disease [ 23 ], an anti-apoptotic role in rheumatoid arthritis [ 24 ] and an anti-inflammatory role in asthma [ 25 ]. Moreover, IL-22 induces psoriasis-like lesions in mice [ 15 ]. Furthermore, IL-22 might be involved in the defense against viruses [ 26 - 27 ], candida albicans [ 28 ] and bact-eria [ 16 , 29 - 31 ]. Several studies have investigated the expression of cytokines, such as TNF- α, IFN-γ, TGF-β, IL-1, 2, 4, 5, 6, 8, 10, 12, 17, 18, and IL-22 in serum, saliva, and lesions in OLP patients [ 32 - 36 ]. Several authors [ 34 - 36 ] have suggested that different cytokines play a role in the initiation and progression of oral lichen planus. Hence, identifying and introducing appropriate immunological targets for diagnostic and therapeutic usage is essential. IL-22 plays a key role in mucosal barrier defense, tissue repair, survival, and proliferation of epithelial cells, but evidence demonstrated both the protective and the pathogenic properties of IL-22 in autoimmune disease, infection, and malignancy [ 37 ]. In the current study, we scrutinized if the IL-22 serum level was different in LP in different forms such as OLP and CLP. Therefore, we measured IL-22 levels in patients’ sera with OLP and CLP in comparison with healthy controls. Materials and Method In this study, 20 OLP patients and 20 CLP patients were selected from individuals, who referred to the dental school, and Molecular Dermatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran (Table 1). Clinical diagnosis and classification of OLP were done by an oral and maxillofacial specialist, and clinical diagnosis of CLP was performed by a dermatologist and confirmed by a pathologist. The IL-22 concentrations in patients and healthy controls were measured using enzyme-linked immunosorbent assay (ELISA) kit (My Biosource, San Diego, California, USA). Results were expressed in pg/ml for IL-22 in serum. Table 1 Baseline characteristics of the investigated patients with oral lichen planus, cutaneous lichen planus, and controls Diagnosis N Mean±Std(age) Age range Women (n) Men (n) Oral LP 20 51.31±13.68 28 ~ 84 16 4 Cutaneous LP 20 43.53±15.95 17 ~72 14 6 Control 32 48.68±9.95 17 ~ 65 25 7 Furthermore, participants were asked if they smoked cigarette, use any drugs, had a history of any surgery, infectious diseases, vaccination, trauma, immune therapy, and chemotherapy. All individuals with items listed above and those with a history of allergy, autoimmunity, immunodeficiency, and cancer were excluded. The control group included 32 healthy individuals who were selected from healthy blood donors in the same age range and gender. Informed consent was obtained from all participants before blood donation and data publication. This study was approved by the local Ethics Committee of Shiraz University of Medical Science (EC-SUMS). Sampling Approximately 5 ml of peripheral blood samples were collected from each participant, and the sera were separated in 3500 rpm for 10 min, stored at -20ºC until further usage. Statistical analysis Data were analyzed using the SPSS software (version 16, Chicago, IL, USA). Kolmogorov-Smirnov and Sha-piro-Wilk tests were used to assess the normal distribution of data. Kruskal–Wallis (one-way ANOVA) test was performed to demonstrate the IL-22 level difference between patients and the controls. P-values less than 0.05 were considered statistically significant. Results In this study, 46 patients with different forms of LP, which included 20 patients with OLP, 20 with CLP and 32 healthy individuals, were examined. There was no significant difference in age between patients and healthy controls. The mean serum levels of IL-22 in patients with different forms of LP and healthy controls are shown in Table 2. The mean serum level of IL-22 in patients with OLP was significantly higher than the healthy controls (p< 0.001). No statistically significant differences were observed in serum levels of IL-22 in CLP patients compared to the controls (p= 0.183). Table 2 Comparison of IL-22 levels in oral and cutaneous lichen planus with the controls Variable IL-22 (pg/ml)± STD N p Value Oral LP 32.4 ± 10 20 < 0.001 Control 24.7 ± 11.7 32 Cutaneous LP 25.95 ± 6.6 20 0.183 Control 24.7 ± 11.7 32 Discussion LP is a chronic autoimmune disease that leads to epithelial cell damage through the infiltration of T lymphocytes and the degeneration of basal keratinocytes. Its mechanism is unclear, but a cytokine complex network plays an important role in the exacerbation and continuity in OLP [ 36 ]. Several studies were showed an abnormal concentration of the levels of various cytokines such as IL-1, 2, 4, 5, 6, 8, 10, 12, 17, 18, 22, TGF-β, IFN-γ, and TNF-α in lesions, serum, OLP. Nonetheless, it is known that some interleukins, saliva, and peripheral mononuclear cells in patients with including TNF-α, IFN-γ, IL-1, 2, 4, 5, 6, 8, 10, 12, 17, 18, 22, are involved in the pathogenesis of OLP [ 32 - 33 ]. IL-22 has both protective and pathogenic roles in different diseases and showed inconsistent results in several studies [ 38 - 40 ]. Furthermore, IL-22 is involved in the pathogenesis of several autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, sjögren syndrome, psoriasis [ 21 ], and skin diseases [ 41 ] but has protective, anti-apoptotic and anti-inflammatory effects in graft versus host disease [ 23 ], rheumatoid arthritis [ 24 ], and asthma [ 25 ]. Previous studies also reported significantly increased IL-22 levels in oral biopsies from patients with OLP compared with the normal controls [ 42 - 43 ]. Besides, the IL-22 level was increased in the lesions of OLP patients, but its level in the serum was inconsistent [ 33 ]. On the contrary, Shirazian et al. [ 44 ] demonstrated an increase in the salivary levels of IL-22 in controls than OLP patients. The present study also showed an elevated level of IL-22 in the serum of patients with OLP but not in CLP patients. The discrepancy between the different results in cytokine levels in OLP in various studies, especially IL-22, can be attributed to the measurement techniques, the genetic background, the polymorphism, the clinical forms, cytokine milieu, gender, and age [ 32 - 33 , 36 - 40 ]. Elevated levels of IL-22 may be due to its protective function against bacterial infections and tissue antigens [ 43 ] or, its increased level may contribute to the pathogenesis of the OLP. But based on some previous studies [ 33 , 43 ], it seems that the pathogenesis role of IL-22 is more prominent. Conclusion IL-22 may play an important role in the pathogenesis of OLP and might serve as a marker for diagnosis of OLP. Therefore, IL-22 antagonists could be a potential therapeutic option. However, extensive researches are needed. Acknowledgement This work was performed as part of Dr. Shiva Torabi Ardakani dissertation as partial fulfillment for her dentistry dissertation at school of dentistry at Shiraz University of Medical Sciences (SUMS). The authors wish to thank Mr. H. Argasi at the Research Consultation Center (RCC) of Shiraz University of Medical Sciences for his invaluable assistance in editing of introduction and results and all participated patients. This project was financially supported by a grant (grand number: 1396-01-03-14575) from department of dentistry, Shiraz University of Medical Sciences, Shiraz, Iran. This study was approved by the Ethics Committee of Shiraz University of Medical Science (IR.SUMS.REC.1396.S686). Informed consent was obtained from each participant before blood donation and data publication. Conflict of Interest: The authors have no affiliations with or involvement in any organization or entity with any financial interest, or non-financial interest in the subject matter or materials discussed in this manuscript. ==== Refs References 1 Baccaglini L Thongprasom K Carrozzo M Bigby M Urban legends series: lichen planus Oral Dis 2013 19 128 143 22788669 2 Farhi D Dupin N Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies Clin Dermatol 2010 28 100 108 20082959 3 Mravak-Stipetić M Lončar-Brzak B Bakale-Hodak I Sabol I Seiwerth S Majstorović M et al Clinicopathologic correlation of oral lichen planus and oral lichenoid lesions: a preliminary study The Scientific World Journal 2014 2014 4 Wagner G Rose C Sachse MM Clinical variants of lichen planus JDDG: Journal der Deutschen Dermatologischen Gesellschaft 2013 11 309 319 23320493 5 Cascone M Celentano A Adamo D Leuci S Ruoppo E Mignogna MD Oral lichen planus in childhood: a case series Int J Dermatol 2017 56 641 652 28256018 6 Cassol-Spanemberg J Blanco-Carrion A Rodriguez-de Rivera-Campillo ME Estrugo-Devesa A Jane-Salas E Lopez-Lopez J Cutaneous, genital and oral lichen planus: A descriptive study of 274 patients Med Oral Patol Oral Cir Bucal 2019 24 e1 e7 30573709 7 Shi P Liu W Zhou Z-T He QB Jiang WW Podoplanin and ABCG2: malignant transformation risk markers for oral lichen planus Cancer Epidemiology and Prevention Biomarkers 2010 19 844 849 8 Sugerman P Savage N Walsh L Zhao Z Zhou X Khan A et al The pathogenesis of oral lichen planus Critical Reviews in Oral Biology & Medicine 2002 13 350 365 12191961 9 Khan A Farah CS Savage NW Walsh LJ Harbrow DJ Sugerman PB Th1 cytokines in oral lichen planus Journal of Oral Pathology & Medicine 2003 32 77 83 12542829 10 Kurago ZB Etiology and pathogenesis of oral lichen planus: an overview Oral surgery, Oral Medicine, Oral Pathology and Oral Radiology 2016 122 72 80 11 Ismail SB Kumar SK Zain RB Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation J Oral Sci 2007 49 89 106 17634721 12 Moudgil KD Choubey D Cytokines in autoimmunity: role in induction, regulation, and treatment Journal of Interferon & Cytokine Research 2011 31 695 703 21942420 13 Perusina Lanfranca M Lin Y Fang J Zou W Frankel T Biological and pathological activities of interleukin-22 J Mol Med (Berl) 2016 94 523 534 26923718 14 Basu R O'Quinn DB Silberger DJ Schoeb TR Fouser L Ouyang W et al Th22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria Immunity 2012 37 1061 1075 23200827 15 Van Belle AB de Heusch M Lemaire MM Hendrickx E Warnier G Dunussi-Joannopoulos K et al IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice J Immunol 2012 188 462 469 22131335 16 Zheng Y Valdez PA Danilenko DM Hu Y Sa SM Gong Q et al Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens Nat Med 2008 14 282 289 18264109 17 Ghoreschi K Laurence A Yang XP Tato CM McGeachy MJ Konkel JE et al Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling Nature 2010 467 967 971 20962846 18 Parks OB Pociask DA Hodzic Z Kolls JK Good M Interleukin-22 Signaling in the Regulation of Intestinal Health and Disease Front Cell Dev Biol 2015 3 85 26793707 19 Eyerich K Dimartino V Cavani A IL-17 and IL-22 in immunity: Driving protection and pathology Eur J Immunol 2017 47 607 614 28295238 20 Tian T Yu S Ma D Th22 and related cytokines in inflammatory and autoimmune diseases Expert Opin Ther Targets 2013 17 113 125 23256771 21 Yang X Zheng SG Interleukin-22: a likely target for treatment of autoimmune diseases Autoimmun Rev 2014 13 615 620 24418299 22 Valeri M Raffatellu M Cytokines IL-17 and IL-22 in the host response to infection Pathog Dis 2016 74 2 23 Pan HF Li XP Zheng SG Ye DQ Emerging role of interleukin-22 in autoimmune diseases Cytokine Growth Factor Rev 2013 24 51 57 22906768 24 Zhao M Li Y Xiao W Anti-apoptotic effect of interleukin-22 on fibroblast-like synoviocytes in patients with rheumatoid arthritis is mediated via the signal transducer and activator of transcription 3 signaling pathway Int J Rheum Dis 2017 20 214 224 27493089 25 Pennino D Bhavsar PK Effner R Avitabile S Venn P Quaranta M et al IL-22 suppresses IFN-gamma-mediated lung inflammation in asthmatic patients J Allergy Clin Immunol 2013 131 562 570 23174657 26 Kim CJ Nazli A Rojas OL Chege D Alidina Z Huibner S et al A role for mucosal IL-22 production and Th22 cells in HIV-associated mucosal immunopathogenesis Mucosal Immunol 2012 5 670 680 22854709 27 Radaeva S Sun R Pan HN Hong F Gao B Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation Hepatology 2004 39 1332 1342 15122762 28 De Luca A Zelante T D'Angelo C Zagarella S Fallarino F Spreca A et al IL-22 defines a novel immune pathway of antifungal resistance Mucosal Immunol 2010 3 361 373 20445503 29 Aujla SJ Chan YR Zheng M Fei M Askew DJ Pociask DA et al IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia Nat Med 2008 14 275 281 18264110 30 Qiao D Yang BY Li L Ma JJ Zhang XL Lao SH et al ESAT-6- and CFP-10-specific Th1, Th22 and Th17 cells in tuberculous pleurisy may contribute to the local immune response against Mycobacterium tuberculosis infection Scand J Immunol 2011 73 330 337 21223348 31 Akagawa KS Recent advances in tuberculosis immunity Kekkaku 2012 87 61 70 22514942 32 Lu R Zhang J Sun W Du G Zhou G Inflammation-related cytokines in oral lichen planus: an overview J Oral Pathol Med 2015 44 1 14 24329772 33 Ma H Wu Y Yang H Liu J Dan H Zeng X et al MicroRNAs in oral lichen planus and potential miRNA-mRNA pathogenesis with essential cytokines: a review Oral Surg Oral Med Oral Pathol Oral Radiol 2016 122 164 173 27282956 34 Larsen KR Johansen JD Reibel J Zachariae C Pedersen AML Serum cytokine profile and clinicopathological findings in oral lichen planus, oral lichenoid lesions and stomatitis Clinical and Experimental Dental Research 2017 3 220 226 29744205 35 Liu WZ He MJ Long L Mu DL Xu MS Xing X et al Interferon-γ and interleukin-4 detected in serum and saliva from patients with oral lichen planus International Journal of Oral Science 2014 6 22 26 24158143 36 Pekiner FN Demirel GY Borahan MO Özbayrak S Cytokine profiles in serum of patients with oral lichen planus Cytokine 2012 60 701 706 22995209 37 Lanfranca MP Lin Y Fang J Zou W Frankel T Biological and pathological activities of interleukin-22 Journal of molecular medicine 2016 94 523 534 26923718 38 Mühl H Scheiermann P Bachmann M Härdle L Heinrichs A Pfeilschifter J IL‐22 in tissue‐protective therapy British Journal of pharmacology 2013 169 761 771 23530726 39 Carmo RF Cavalcanti MS Moura P Role of Interleukin-22 in chronic liver injury Cytokine 2017 98 107 14 27816383 40 Dudakov JA Hanash AM van den Brink MR Interleukin-22: immunobiology and pathology Annual review of Immunology 2015 33 747 785 41 Fujita H Role of IL-22 in the pathogenesis of skin diseases Nihon Rinsho Men'eki Gakkai Kaishi, Japanese Journal of Clinical Immunology 2012 35 168 175 22790576 42 Shen Z Du G Zhou Z Liu W Shi L Xu H Aberrant expression of interleukin‐22 and its targeting micro RNA s in oral lichen planus: a preliminary study Journal of Oral Pathology & Medicine 2016 45 523 527 26711064 43 Chen J Feng J Chen X Xu H Zhou Z Shen X et al Immunoexpression of interleukin-22 and interleukin-23 in oral and cutaneous lichen planus lesions: a preliminary study Mediators Inflamm 2013 2013 801974 24376306 44 Shirazian S Aghahosseini F Salehi E Vatanpour M Banijamali SN Pourshahidi S Comparison of interleukin 17 and 22 in saliva of oral lichen planus patients with healthy people Bioscience Biotechnology Research Communications 2017 10 587 591